| Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. | |
| | |
MedLine Citation:
|
PMID: 7863974 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atherogenic dyslipidemia is a lipoprotein profile combining 4 specific abnormalities: borderline-high total cholesterol levels; high triglyceride concentrations; small, dense, low-density lipoprotein (LDL) particles; and low high-density lipoprotein (HDL) concentrations. It is a predisposing factor to premature coronary artery disease (CAD), although separating and calculating the contribution of each abnormality to the risk of CAD is difficult, especially since the abnormalities often appear in this combination. The ratio of total cholesterol to HDL cholesterol is currently the most powerful single predictor of risk in dyslipidemic patients. Therapy for atherogenic dyslipidemia includes dietary changes aimed at decreasing intake of cholesterol-raising fatty acids and achieving weight reduction; exercise, which confers many of the benefits of weight reduction; and, when those measures fail to correct the lipid and lipoprotein profile, drug therapy. Nicotinic acid reduces triglyceride and cholesterol levels while raising HDL concentrations, but up to half of patients cannot tolerate its adverse effects. Fibric acids effectively lower triglyceride levels and are generally well tolerated but have little beneficial effect on the cholesterol profile. Statins offer marked reductions in total, LDL, and very low-density lipoprotein cholesterol levels and cause modest increases in HDL concentration. Combination therapy can enhance the efficacy of the individual drugs. |
| | |
Authors:
|
S M Grundy |
Related Documents
:
|
1733134 - Results of surgery: long-term effects on hyperlipidemia. 15120444 - Cholesterol lowering effect of sg-gn3, the extract of salted and fermented small shrimp... 9315524 - Passive cigarette smoking and reduced hdl cholesterol levels in children with high-risk... 3896224 - Cholesterol, stress, lifestyle, and coronary heart disease. 17203164 - Dietary beta-cryptoxanthin inhibits n-butyl-n-(4-hydroxybutyl)nitrosamine-induced urina... 21979454 - Indices using external measurements for assessing fat deposition of adult feral raccoon... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of cardiology Volume: 75 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1995 Feb |
Date Detail:
|
Created Date: 1995-03-23 Completed Date: 1995-03-23 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 45B-52B Citation Subset: AIM; IM |
Affiliation:
|
Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas 75235-9052. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Arteriosclerosis
/
blood,
etiology*,
therapy* Coronary Disease / blood, etiology, therapy Humans Hyperlipidemias / blood, complications*, therapy* Lipoproteins / blood* Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Lipoproteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimal intensity and monitoring warfarin.
Next Document: Dense low density lipoproteins and coronary artery disease.